关注 “环球资源外贸” 官方微信，获取实时外贸资讯
Product Information
Key Specifications/ Special Features
RT5, whose active ingredient is RT, is a triple receptor agonist peptide targeting GLP‑1, GIP and glucagon receptors, exclusively supplied for laboratory research purposes only. Each individual vial contains 5 mg lyophilized white peptide powder, with HPLC verified purity exceeding 99.5%, free of irrelevant excipients and irritants.
It adopts a three-pathway synergistic metabolic regulation mechanism that differentiates it from dual agonist peptides such as TR30. Before subcutaneous injection for research testing, RT5 dry powder must be reconstituted with bacteriostatic water. Unreconstituted lyophilized powder requires airtight low-temperature storage below 8°C, while diluted peptide solution remains stable for a maximum of 28 days under refrigeration. This product has not obtained global approval for human clinical treatment or cosmetic administration, and can only be used for in-vitro cell experiments and animal metabolic research projects.
RT5 activates multiple glucose metabolic pathways simultaneously. It stimulates glucose-dependent insulin secretion from pancreatic islets and suppresses excessive hepatic glucagon output, effectively lowering fasting blood sugar and postprandial blood glucose spikes. Long-term research data shows it can reduce glycated hemoglobin levels and alleviate chronic insulin resistance in metabolic disorder models, with a lower risk of hypoglycemia compared with single-target peptides.
The glucagon receptor activation unique to RT5 accelerates lipolysis and basal metabolic rate, converting white adipose tissue into energy-consuming brown fat. Combined with delayed gastric emptying to cut calorie intake, it preferentially eliminates harmful visceral fat rather than lean muscle mass, delivering more significant steady weight loss effects than dual-action peptides in animal trials.
It acts on the hypothalamic satiety center to prolong fullness after meals and suppress cravings for high-sugar, high-calorie foods. The slow gastric emptying effect stabilizes eating frequency and naturally cuts daily total calorie intake, supporting continuous, controllable weight management without extreme dieting.
RT5 optimizes overall lipid profiles by reducing triglycerides and low-density lipoprotein. It relieves obesity-induced hypertension and sleep apnea, mitigates oxidative vascular damage, and shows potential auxiliary regulatory effects on non-alcoholic fatty liver disease and polycystic ovary syndrome (PCOS). It also delivers mild cardioprotective benefits by reducing metabolic inflammatory markers in circulation.
RT5, whose active ingredient is RT, is a triple receptor agonist peptide targeting GLP‑1, GIP and glucagon receptors, exclusively supplied for laboratory research purposes only. Each individual vial contains 5 mg lyophilized white peptide powder, with HPLC verified purity exceeding 99.5%, free of irrelevant excipients and irritants.
It adopts a three-pathway synergistic metabolic regulation mechanism that differentiates it from dual agonist peptides such as TR30. Before subcutaneous injection for research testing, RT5 dry powder must be reconstituted with bacteriostatic water. Unreconstituted lyophilized powder requires airtight low-temperature storage below 8°C, while diluted peptide solution remains stable for a maximum of 28 days under refrigeration. This product has not obtained global approval for human clinical treatment or cosmetic administration, and can only be used for in-vitro cell experiments and animal metabolic research projects.
RT5 activates multiple glucose metabolic pathways simultaneously. It stimulates glucose-dependent insulin secretion from pancreatic islets and suppresses excessive hepatic glucagon output, effectively lowering fasting blood sugar and postprandial blood glucose spikes. Long-term research data shows it can reduce glycated hemoglobin levels and alleviate chronic insulin resistance in metabolic disorder models, with a lower risk of hypoglycemia compared with single-target peptides.
The glucagon receptor activation unique to RT5 accelerates lipolysis and basal metabolic rate, converting white adipose tissue into energy-consuming brown fat. Combined with delayed gastric emptying to cut calorie intake, it preferentially eliminates harmful visceral fat rather than lean muscle mass, delivering more significant steady weight loss effects than dual-action peptides in animal trials.
It acts on the hypothalamic satiety center to prolong fullness after meals and suppress cravings for high-sugar, high-calorie foods. The slow gastric emptying effect stabilizes eating frequency and naturally cuts daily total calorie intake, supporting continuous, controllable weight management without extreme dieting.
RT5 optimizes overall lipid profiles by reducing triglycerides and low-density lipoprotein. It relieves obesity-induced hypertension and sleep apnea, mitigates oxidative vascular damage, and shows potential auxiliary regulatory effects on non-alcoholic fatty liver disease and polycystic ovary syndrome (PCOS). It also delivers mild cardioprotective benefits by reducing metabolic inflammatory markers in circulation.
,Manufacturer ,Online Seller ,Importer 